About
Mission and Values
Leadership Team
Management Team
Scientific Advisory Board
Corporate Governance
Technology
Introduction
Allogeneic CAR T Cell Therapy
OnCARlytics (CF33-CD19)
Oncolytic Virus (CF33)
B-Cell Immunotherapies
Publications
Pipeline
Clinical Pipeline
Clinical Trials
Investors
ASX Announcements
Investor Presentations
Conference Presentations
Analyst Coverage
Annual Reports
Half Yearly Report
Quarterly Report
Live Share Price
Media
Videos
Newsletters
ESG Reports
Contact

Imugene (ASX: IMU)

About
Mission and Values
Leadership Team
Management Team
Scientific Advisory Board
Corporate Governance
Technology
Introduction
Allogeneic CAR T Cell Therapy
OnCARlytics (CF33-CD19)
Oncolytic Virus (CF33)
B-Cell Immunotherapies
Publications
Pipeline
Clinical Pipeline
Clinical Trials
Investors
ASX Announcements
Investor Presentations
Conference Presentations
Analyst Coverage
Annual Reports
Half Yearly Report
Quarterly Report
Live Share Price
Media
Videos
Newsletters
ESG Reports
Contact
iStock-943292690.jpg

Announcements

  • Investors
  • ASX Announcements
  • Investor Presentations
  • Conference Presentations
  • Analyst Coverage
  • Annual Reports
  • Half Yearly Report
  • Quarterly Report
  • Live Share Price
  • Media
  • Videos
  • Newsletters
  • ESG Reports
Back to Top
Imugene Limited, Suite 12.01, Level 12, 4-6 Bligh Street, Sydney, NSW, 2000, Australia

Imugene Limited ABN 99 009 179 551 Australia

Imugene acknowledge the Traditional Owners of the land on which it operates and pays respect to Elders past, present and emerging.

Site by BDAC